期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 32, 期 1, 页码 25-35出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2023.2169127
关键词
Countermeasure; gamma-tocotrienol; mice; proteomics; metabolomics; nonhuman primates; polypharmacy; radiation injury
The need for radiation medical countermeasures is growing due to the increasing possibility of radiological and nuclear emergencies. Gamma-tocotrienol, a component of vitamin E, is a promising radiation countermeasure that has shown significant efficacy in animal models of acute radiation syndrome.
IntroductionThe possibility of exposure to high doses of total- or partial-body ionizing radiation at a high dose rate due to radiological/nuclear accidents or terrorist attacks is increasing. Despite research and development during the last six decades, there is a shortage of nontoxic, safe, and effective radiation medical countermeasures (MCMs) for radiological and nuclear emergencies. To date, the US Food and Drug Administration (US FDA) has approved only four agents for the mitigation of hematopoietic acute radiation syndrome (H-ARS).Area coveredWe present the current status of a promising radiation countermeasure, gamma-tocotrienol (GT3; a component of vitamin E) as a radiation MCM that has been investigated in murine and nonhuman primate models of H-ARS. There is significant work with this agent using various omic platforms during the last few years to identify its efficacy biomarkers.Expert opinionGT3 is a newer type of radioprotector having significant injury-countering potential and is currently under advanced development for H-ARS. As a pre-exposure drug, it requires only single doses, lacks significant toxicity, and has minimal, ambient temperature storage requirements; thus, GT3 appears to be an ideal MCM for military and first responders as well as for storage in the Strategic National Stockpile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据